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MaOBJECTIVES This study aimed to assess the clinical impact of strut width (evaluated by abluminal strut surface area
[ASSA]) on periprocedural myocardial infarction (PMI) and clinical outcomes in patients treated with bioresorbable
scaffolds (BRS) versus ﬁrst-generation sirolimus-eluting stents (SES).
BACKGROUND To date, there are no reports on the impact of ASSA on PMI and clinical outcomes.
METHODS We compared the impact of ASSA on outcomes and PMI in propensity-matched patients treated with BRS
and SES. The primary outcome was the incidence of major adverse cardiac events (MACE), deﬁned as the combination of
all-cause mortality, follow-up myocardial infarction, and target vessel revascularization, at 30-days and 1-year follow-
ups. The secondary endpoint was the incidence of PMI.
RESULTS After propensity-matched analysis, 499 patients (147 BRS patients vs. 352 SES patients) were evaluated.
Mean ASSA was higher in patients treated with BRS versus SES (BRS: 132.3  76.7 mm2 vs. SES: 67.6  48.4 mm2,
p < 0.001). MACE was not signiﬁcantly different between groups (30-days MACE: BRS: 0% vs. SES: 1.4%, p ¼ 0.16, and
1-year MACE: BRS: 15.7% vs. SES: 11.4%, p ¼ 0.67). The incidence of PMI was signiﬁcantly higher in the BRS group
(BRS: 13.1% vs. SES: 7.5%, p ¼ 0.05). Multivariable analyses indicated that treatment of left anterior descending artery
and ASSA were independent predictors of PMI.
CONCLUSIONS BRS implantation, compared with SES implantation, was associated with a higher incidence of PMI.
MACE at 30 days and 1 year were not signiﬁcantly different. Left anterior descending artery percutaneous coronary
intervention and ASSA were independent predictors of PMI. (J Am Coll Cardiol Intv 2015;8:900–9) © 2015 by the
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AB BR E V I A T I O N S
AND ACRONYM S
ASSA = abluminal strut
surface area
BRS = bioresorbable
scaffold(s)
CABG = coronary artery
bypass graft
CI = conﬁdence interval
CK-MB = creatine kinase-
myocardial band
DES = drug-eluting stent(s)
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901post-implantation and have the potential to restore
normal vasomotor function (11,12). Furthermore, the
absorption of struts does not preclude future surgical
revascularization should the need arise. The ABSORB
A (Bioabsorbable Vascular Solutions First in Man
Clinical Investigation: A Clinical Evaluation of the
Bioabsorbable Vascular Solutions Everolimus Eluting
Coronary Stent System in the Treatment of Patients
With Single De Novo Native Coronary Artery Lesions)
trial demonstrated favorable short-term and late
clinical outcomes out to 5 years in patients with
relatively simple coronary lesions (13).SEE PAGE 910
LAD = left anterior descending
coronary artery
MACE = major adverse
cardiac events
MI = myocardial infarction
OR = odds ratio
PCI = percutaneous coronary
intervention
PMI = periprocedural
myocardial infarction
SES = sirolimus-eluting
stent(s)
ST = stent thrombosis
TLR = target lesion
revascularization
TVR = target vessel
revascularizationThe strut thickness of the Absorb (version 1.1,
Abbott Vascular, Santa Clara, California) BRS is 157
mm, which is comparable to that of the Cypher ﬁrst-
generation sirolimus-eluting stents (SES) (Cypher Bx
Velocity and Cypher Select, Cordis Corporation,
Johnson & Johnson, Warren, New Jersey), which is
152.6 mm (14,15). To secure sufﬁcient radial strength
and prevent acute scaffold recoil, the current BRS
needs not merely increased strut thickness but also
strut width ﬁgures (2.5- and 3.0-mm BRS: 190.5 mm,
and 3.5-mm BRS: 215.9 mm) that are much wider than
those of SES (strut width of all SES sizes: 130 mm). DES
with thicker struts have been associated with more
angiographic and clinical restenosis than the thinner-
strut stents have, especially when treating small
coronary vessels (16). Moreover, the wider struts of
BRS may lead to a higher prevalence of side branch
occlusion and periprocedural myocardial infarction
(PMI) (17,18). PMI has in turn been related to higher
occurrences of short-term and late clinical outcomes
(19–21). In the ABSORB EXTEND (ABSORB EXTEND
Clinical Investigation: A Continuation in the Clinical
Evaluation of the ABSORB Bioresorbable Vascular
Scaffold System in the Treatment of Subjects With De
Novo Native Coronary Artery Lesions) substudy, BRS
implantation was associated with a higher incidence
of post-procedural side branch occlusions than
everolimus-eluting stent implantation was (22).
METHODS
STUDY POPULATION. A retrospective analysis in 2
high volume centers in Milan, Italy, was performed
on 157 consecutive patients who underwent percuta-
neous coronary intervention (PCI) with Absorb BRS
between May 1, 2012 and April 30, 2014, and 895 pa-
tients who were implanted with the SES (Cypher)
between January 1, 2004 and October 30, 2009.
Exclusion criteria included PCI for ST-segment
elevation myocardial infarction, non–ST-segmentelevation myocardial infarction, bypass
grafting, bifurcation lesions treated with a 2-
stent/scaffold strategy, and patients with
end-stage renal failure (on hemodialysis). If
2 stents/scaffolds were implanted with over-
lap of more than 10 mm length by quantita-
tive coronary angiography, the lesions were
excluded from this study. The total study
population is described in Figure 1. Of the
total 1,052 patients, 990 patients were
assessed for eligibility (150 patients in BRS
group, and 840 patients in SES group). All
patients provided written informed consent,
according to the Declaration of Helsinki. All
clinical data at follow-up were collected from
hospital visits or telephone consultations.
STUDY DEVICES. The details of each device
(BRS group: Absorb, Abbott Vascular; and
SES group: Cypher, Cordis Corporation) are
presented in Figure 2. Although both types
of stents are constructed with a similar strut
thickness (BRS: 157 mm vs. SES: 152.6 mm),
their strut-width components differ at the
narrow link part (BRS: 140 mm vs. SES: 60 mm)
and at the wide hoop part (2.5- and 3.0-mm
BRS: 190.5 mm, 3.5-mm BRS: 215.9 mm vs.
130 mm; all sizes of SES). As an index repre-
senting the strut width, we used the abluminal
strut surface area (ASSA). ASSA was calculated using
the percentages of stent or scaffold surface area/vessel
surface area (c)
h
ASSA ðmm2Þ ¼ stent diameter ðmmÞ
p c100stent length ðmmÞ
i
(Figure 2). If more than 2
stents/scaffolds were implanted, the ASSA of the each
stent/scaffold was calcu-lated and summed regardless
of the stent/scaffold overlapping.
STUDY DEFINITIONS. Death was considered cardiac
in origin unless obvious noncardiac causes were
identiﬁed. The deﬁnition of myocardial infarction
(MI) was an increase in the creatine kinase level to
greater than twice the upper limit of the normal,
accompanied by an increased level of creatine kinase-
myocardial band (CK-MB). In the absence of CK, it
was deﬁned as an increase in the CK-MB level over 3
the upper limit of normal. PMI was classiﬁed as MI
occurring within 48 h after PCI (23). Target lesion
revascularization (TLR) was deﬁned as repeat PCI or
coronary artery bypass graft (CABG) for the lesion in
the previously stented segment or in the adjacent
5 mm. Target vessel revascularization (TVR) was
deﬁned as PCI or CABG of the target lesion or any
segment of the epicardial coronary artery containing
the target lesion. Stent thrombosis (ST) was classiﬁed
FIGURE 1 Chart Demonstrating the Study Design and the Inclusion Criteria
Of the total 1,052 patients, 990 patients were assessed for eligibility (150 patients in the
BRS group, and 840 patients in the SES group). If 2 stents/scaffolds were implanted with
an overlap of more than 10 mm length by quantitative coronary angiography, the lesions
were excluded from this study. BRS ¼ bioresorbable scaffold; NSTEMI ¼ non–ST-segment
elevation myocardial infarction; PCI ¼ percutaneous coronary intervention; SES ¼
sirolimus-eluting stent; STEMI ¼ ST-segment elevation myocardial infarction.
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902according to the Academic Research Consortium
deﬁnitions and cumulative ST as a combination of all
episodes of ST during follow-up (24).
Quantitative coronary angiographic analyses were
performed by 2 experienced cardiologists (H.K. and
T.N.). Minimum lumen diameter, percentage of dia-
meter stenosis, and reference vessel diameter were
evaluated using a validated edge detection system
(CMS, version 5.2, Medis Medical Imaging Systems BV,
Leiden, the Netherlands).
ENDPOINTS. The primary endpoint was the rate of
major adverse cardiac events (MACE) deﬁned as the
combination of all-cause mortality, follow-up MI (af-
ter 48-h post-index procedure), and TVR at 30-days
and 1-year follow-ups. The secondary endpoint was
the incidence of PMI.
STATISTICAL ANALYSIS. All continuous variables
were tested for normality using the Kolmogorov-
Smirnov test. Continuous variables are presented as
the mean  SD or the median  interquartile range
(25th to 75th percentile) for normally and not normally
distributed variables, respectively. Differences in
continuous variables between groups were analyzed
using Student t test or Mann-Whitney U test. After
propensity matching, differences in continuous vari-
ables were analyzed using paired t test. Categorical
variables are expressed as numeric values andpercentages. Categorical data were compared using
the chi-square or Fisher exact tests (overall cohort) or
the McNemar test (propensity-matched cohort). The
cumulative incidences were generated using Kaplan-
Meier analysis, and the signiﬁcance of observed dif-
ferences was assessed with the log-rank test (overall
cohort) or Klein–Moeschberger test (propensity-
matched cohort). To identify the independent risk
factors of PMI, we performed multivariable logistic
regression analysis using the following covariates: all
variables with values of p < 0.10 on the univariate
analysis and those judged to be of clinical signiﬁcance
(chronic kidney disease, insulin-dependent diabetes
mellitus, and acute gain). The multivariable model
was created with a stepwise elimination procedure,
where the independent variables were entered into
the model at the 0.20 signiﬁcance level and removed
at the 0.25 level. To avoid overﬁtting, the number of
independent variables entered into the ﬁnal multi-
variable logistic regression model was limited to 1 for
every 8 to 10 events. The results are reported as
odds ratios (ORs) and 95% conﬁdence intervals (CIs).
Analyses were performed using SPSS (version 20.0,
SPSS Inc., Chicago, Illinois) and R (version 2.12, R
Development Core Team, Vienna, Austria). All re-
ported p values were 2-sided, and values of p < 0.05
were regarded as statistically signiﬁcant.
To reduce the effect of treatment selection bias and
other confounding in this retrospective study with
different recruitment periods, we performed pro-
pensity score matching. The propensity scores were
estimated using multiple logistic regression analysis
including the following baseline patient or procedural
characteristics as covariates: previous MI, previous
CABG, family history of coronary artery disease, his-
tory of smoking, dyslipidemia, diabetes mellitus,
insulin-dependent diabetes mellitus, PCI of the left
anterior descending coronary artery (LAD), use of
rotational atherectomy, stent/scaffold post-dilation,
total stent or scaffold length, and total number of
treated vessels. Considering the larger number of
patients in the SES group (n ¼ 840) than in the BRS
group (n ¼ 150), a multiple matching (BRS:SES ¼ 1:3)
was performed in this study. After propensity score
matching, all of the standardized differences for
each of the baseline variables were <0.10 (10%).
RESULTS
STUDY POPULATION. Of the total of 990 patients
who met the inclusion criteria (150 patients in the
BRS, and 840 patients in the SES group), the pro-
pensity score was not calculable for 89 patients in
the SES group due to missing values in baseline
FIGURE 2 Strut Thickness, Width, and Abluminal Strut Surface Area of Absorb BRS and Cypher SES
Abluminal strut surface area (ASSA) was calculated using percentage of vessel area covered by stent or scaffold (%). If more than 2 stents/
scaffolds were implanted, the ASSAs of the each stent/scaffold were calculated and summed regardless of the stent/scaffold overlapping.
Absorb (Abbott Vascular, Santa Clara, California) BRS and Cypher (Cordis Corporation, Johnson & Johnson, Warren, New Jersey). Abbreviations
as in Figure 1.
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903characteristics. Therefore, 147 patients in the BRS
group were matched with 352 patients in the SES
group in the current analysis (Figure 1).
BASELINE CHARACTERISTICS. The baseline clinical
and lesion characteristics of the BRS and SES group
were compared, as shown in Table 1. In the overall
cohort, the SES group had a signiﬁcantly higher rate of
previous MI, previous CABG, family history of coro-
nary artery disease, and dyslipidemia than the BRS
group did. In addition, the number of treated vessels
was smaller, and ejection fraction was higher in the
BRS group than in the SES one. In the matched cohort,
there were no longer any signiﬁcant differences in
the aforementioned covariates between the 2 groups.The lesion characteristics in both groups were also
comparable, as shown in Table 2. Only few procedural
characteristics remained signiﬁcantly different be-
tween the 2 groups after propensity matching.
Namely, the prevalence of pre-dilation and usage of
intravascular ultrasound was higher in the BRS group.
There was also a signiﬁcant difference in the treated
target vessel, with a lower rate of the right coronary
artery being treated in the BRS group (BRS: 12.7% vs.
SES: 21.7%, p ¼ 0.001). Although the BRS group had
lower percentage of diameter stenosis and acute gain,
there were no signiﬁcant differences in stent or
scaffold sizes, ﬁnal reference vessel diameter or
minimum lumen diameter sizes. Mean ASSA was
TABLE 1 Patient Demographic and Procedural Characteristics in the Overall and the Propensity-Matched Cohort
Overall Cohort Propensity-Matched Cohort
BRS (n ¼ 150) SES (n ¼ 840) p Value BRS (n ¼ 147) SES (n ¼ 352) p Value
Procedures 162 895 159 381
Patient characteristics
Age, yrs 64.0  11.2 63.6  10.6 0.65 63.9  11.3 64.4  10.6 0.66
Male 135 (90.0) 719 (85.6) 0.15 132 (89.8) 296 (84.1) 0.10
Previous MI 39 (26.0) 386 (46.0) <0.001 39 (26.5) 119 (33.8) 0.11
Previous PCI 72 (48.0) 380 (45.2) 0.53 71 (48.3) 145 (41.2) 0.14
Previous CABG 11 (7.3) 132 (15.7) 0.007 11 (7.5) 36 (10.2) 0.34
Family history of CAD 62 (41.3) 431 (51.3) 0.02 61 (41.5) 178 (50.6) 0.06
Hypertension 94 (62.7) 548 (65.2) 0.54 91 (61.9) 219 (62.2) 0.95
Dyslipidemia 89 (59.3) 566 (67.4) 0.06 88 (59.9) 222 (63.1) 0.50
History of smoking 79 (52.7) 413 (49.2) 0.43 76 (51.7) 158 (44.9) 0.16
DM 41 (27.3) 226 (26.9) 0.91 40 (27.2) 82 (23.3) 0.35
Insulin dependent DM 11 (7.3) 52 (6.2) 0.60 10 (6.8) 18 (5.1) 0.46
eGFR < 60 (ml/min/1.73 m2) 76 (51.4) 234 (46.3) 0.25 75 (51.7) 164 (46.9) 0.32
Ejection fraction < 35% 3 (2.3) 38 (4.8) 0.20 3 (2.0) 14 (4.0) 0.28
Procedural characteristics
Total number of stents/scaffolds 2.2  1.1 2.1  1.4 0.79 2.1  1.1 2.1  1.4 0.99
Total stent/scaffold length, mm 51.2  29.4 54.3  38.8 0.24 50.8  29.5 54.6  39.0 0.22
Stent/scaffold diameter, mm 2.99  0.31 2.93  0.39 0.04 2.99  0.31 2.94  0.41 0.11
Number of treated vessels 1.2  0.5 1.5  0.7 <0.001 1.3  0.5 1.3  0.6 0.15
ASSA, mm2 133.3  76.5 67.4  48.9 <0.001 132.3  76.7 67.6  48.4 <0.001
Values are n (%) or mean  SD.
ASSA ¼ abluminal strut surface area; BRS ¼ bioresorbable scaffold(s); CABG ¼ coronary artery bypass graft; CAD ¼ coronary artery disease; DM ¼ diabetes mellitus; eGFR ¼
estimated glomerular ﬁltration rate; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention; SES ¼ sirolimus-eluting stent(s).
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904higher in patients treated with BRS versus SES (BRS:
132.3  76.7 mm2 vs. SES: 67.6  48.4 mm2, p < 0.001).
MAJOR ADVERSE CARDIAC EVENTS AND PERI-
PROCEDURAL MYOCARDIAL INFARCTION. The clin-
ical outcomes at 30- days and 1 year are shown in
Table 3. There were no signiﬁcant differences in
MACE (MACE at 30 days: BRS: 0% vs. SES: 1.4%,
p ¼ 0.15, and MACE at 1 year: BRS: 15.7% vs. SES:
11.4%, p ¼ 0.61) or their individual components
(Figure 3). MACE rates were mainly driven by TVR in
both groups (BRS: 14.1% vs. SES: 9.4%, p ¼ 0.36). On
the other hand, the incidence of PMI was signiﬁcantly
higher in the BRS group than in the SES group (BRS:
19 [13.1%] vs. SES: 26 [7.5%], p ¼ 0.05). In our study,
deﬁnite ST occurred in 1 patient treated with BRS and
3 patients treated with SES, with no statistical sig-
niﬁcant differences between the 2 groups (BRS: 0.9%
vs. SES: 0.9%, p ¼ 0.89).
PREDICTORS OF PERIPROCEDURAL MYOCARDIAL
INFARCTION. Univariate analysis revealed the
following risk factors for PMI: BRS (OR: 1.86, 95% CI:
1.00 to 3.47, p ¼ 0.05), LAD (OR: 2.84, 95% CI: 1.24 to
6.50, p ¼ 0.01), pre-dilation (OR: 4.37, 95% CI: 1.03 to
18.50, p ¼ 0.05), post-dilation (OR: 0.15, 95% CI: 0.02to 0.93, p ¼ 0.04), total stent or scaffold number (OR:
1.33, 95% CI: 1.10 to 1.61, p ¼ 0.003), total stent or
scaffold length (OR [per 10-mm increase]: 1.10, 95%
CI: 1.03 to 1.18, p ¼ 0.004), and ASSA (OR [per 10-mm2
increase]: 1.07, 95% CI: 1.03 to 1.12, p < 0.001). The
covariates entered into the ﬁnal logistic regression
model included LAD PCI, insulin-dependent diabetes
mellitus, pre-dilation, total stent or scaffold length,
and ASSA. Multivariable analyses indicated LAD PCI
and ASSA to be independent predictors of PMI (LAD
PCI OR: 2.60, 95% CI: 1.16 to 5.81, p ¼ 0.02, and ASSA
OR [per 10-mm2 increase]: 1.07, 95% CI: 1.03 to 1.12,
p ¼ 0.001) (Table 4). The C-statistic was 0.69, and the
Hosmer-Lemeshow test p value was 0.58, conﬁrming
good discrimination and calibration of the logistic
regression model, respectively.DISCUSSION
The present study is the ﬁrst comparison between
BRS and SES, demonstrating the clinical impact of
strut width on PMI and 1-year clinical outcomes. The
main ﬁndings of our study are the following: 1) the
incidence of PMI was higher among patients treated
with BRS versus SES despite similar strut thickness;
TABLE 2 Lesion and Procedural Characteristics in the Overall and the Propensity-Matched Cohort
Overall Cohort Propensity-Matched Cohort
BRS
(n ¼ 202)
SES
(n ¼ 1,219) p Value
BRS
(n ¼ 197)
SES
(n ¼ 492) p Value
In-stent restenosis 15 (7.5) 121 (9.9) 0.27 15 (7.6) 40 (8.1) 0.82
Chronic total occlusion 12 (6.0) 121 (9.9) 0.07 12 (6.1) 47 (9.6) 0.14
Rotational atherectomy 8 (4.0) 30 (2.5) 0.22 6 (3.0) 8 (1.6) 0.23
Pre-dilation 198 (99.0) 811 (73.7) <0.001 195 (99.0) 391 (79.5) <0.001
Post-dilation 200 (99.5) 628 (57.8) <0.001 196 (99.5) 482 (98.0) 0.15
IVUS 159 (79.1) 266 (21.8) <0.001 156 (79.2) 145 (29.5) <0.001
Target vessel
LAD 121 (60.2) 498 (40.9) <0.001 117 (59.4) 255 (51.8) 0.07
LCX 51 (25.4) 334 (27.4) 0.55 51 (25.9) 112 (22.8) 0.38
RCA 25 (12.4) 325 (26.7) <0.001 25 (12.7) 107 (21.7) 0.01
Type B2/C lesion (ACC/AHA) 162 (80.6) 956 (78.4) 0.49 158 (80.2) 413 (83.9) 0.24
Number of stents/scaffolds 1.7  0.8 1.6  0.8 0.02 1.7  0.8 1.6  0.9 0.27
Stent/scaffold length, mm 41.3  22.4 40.2  25.1 0.56 40.9  22.3 41.7  27.4 0.7
Stent/scaffold diameter, mm 3.00  0.34 2.94  0.39 0.02 3.00  0.34 2.95  0.39 0.08
RVD, mm 2.82  0.51 2.74  0.66 0.07 2.81  0.51 2.75  0.66 0.24
MLD, mm 0.88  0.48 0.80  0.55 0.08 0.88  0.49 0.76  0.54 0.02
Percentage stenosis, % 68.5  17.4 74.1  16.0 <0.001 68.4  17.6 74.3  16.7 <0.001
Final RVD, mm 3.09  0.47 3.11  0.55 0.6 3.10  0.48 3.15  0.55 0.23
Final MLD, mm 2.70  0.49 2.71  0.55 0.81 2.69  0.49 2.75  0.54 0.23
Acute gain, mm 1.83  0.64 1.97  0.61 0.007 1.83  0.64 2.03  0.60 <0.001
Pre-balloon size, mm 2.84  0.35 2.51  0.49 <0.001 2.84  0.36 2.56  0.49 <0.001
Post-balloon size, mm 3.24  0.42 3.17  0.47 0.09 3.23  0.42 3.17  0.45 0.12
Post-balloon pressure, atm 20.8  4.5 18.8  5.3 <0.001 20.8  4.5 18.9  5.3 <0.001
Post-balloon/stent or scaffold ratio 1.08  0.09 1.05  0.10 <0.001 1.08  0.09 1.06  0.10 0.01
Values are n (%) or mean  SD.
ACC/AHA¼ American College of Cardiology/American Heart Association; IVUS¼ intravascular ultrasound; LAD ¼ left anterior descending artery; LCX¼ left circumﬂex artery;
MLD ¼ minimum lumen diameter; RCA ¼ right coronary artery; RVD ¼ reference vessel diameter.
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9052) there were no signiﬁcant differences in clinical
outcomes between the BRS group and the SES group;
3) LAD PCI and ASSA were independent predictors of
PMI.
PMI is mainly related to either side branch occlu-
sion or iatrogenic plaque rupture by balloons and
stents (25,26). In the bare-metal stent era, although
bare-metal stents reduced acute major complications,
a paradoxical increase in the incidence of PMI was
reported after stent implantation compared with that
of balloon angioplasty (27). In the early DES era, the
greater strut thickness of the ﬁrst-generation DES had
been implicated in a higher incidence of side branch
occlusion and PMI than had the second-generation
DES with thinner struts (17,18). With the advent of
BRS, a main concern was the higher incidence of post-
procedural side branch occlusion compared with that
of second-generation DES (22). In our study, the
univariable model revealed both total stent or scaf-
fold length and ASSA to be risk factors for PMI. After
multivariable analysis, however, the latter was the
only independent predictor of PMI. The comparison
between BRS and SES, stents with similar strutthickness but different strut widths, highlights the
impact of strut width on PMI. ASSA can resolve these
discrepancies in strut dimensions between stents and
provide a more comprehensive quantiﬁcation of strut
size and its impact on periprocedural outcomes. Even
though ASSA is affected by stent design and strut
platforms, it is mainly inﬂuenced by strut width. This
implies that the strut width is among the most
important factors for PMI. As shown in Figure 2, ASSA
of BRS is approximately 2 larger than that of SES
when comparing devices of the same diameter (e.g.,
3.0-mm BRS ¼ 2.544  scaffold length, and 3.0-mm
SES [Cypher Bx] ¼ 1.272  stent length). This differ-
ence could have an impact on both the incidence of
side branch occlusion and PMI. BRS scaffold expan-
sion is more asymmetric than that of metal stents
(28). This asymmetric expansion of BRS with its wider
struts may lead to nonuniform strut distribution and
result in a more frequent incidence of side branch
occlusions and PMI. The other independent predictor
of PMI in this study was PCI for the LAD. LAD
generally has many small branches such as septal and
diagonal branches and supplies a larger territory,
TABLE 3 Incidence of PMI and Estimated Incidences (Kaplan-Meier Analysis) of
Outcomes at 30 Days and 1 Year
Overall Cohort Propensity-Matched Cohort
BRS
(n ¼ 150)
SES
(n ¼ 840)
p
Value
BRS
(n ¼ 147)
SES
(n ¼ 352)
p
Value
Procedures 162 895 159 381
PMI 20 (13.5) 52 (6.3) 0.002 19 (13.1) 26 (7.5) 0.05
Clinical outcomes at 30 days
MACE 0 11 (1.3) 0.16 0 5 (1.4) 0.16
All-cause death 0 5 (0.6) 0.35 0 2 (0.6) 0.41
Follow-up MI 0 8 (1.0) 0.23 0 4 (1.1) 0.20
TLR (per lesion) 0 5 (0.4) 0.36 0 1 (0.2) 0.62
TVR (per patient) 0 5 (0.6) 0.35 0 2 (0.4) 0.36
Clinical outcomes at 1 year
MACE 12 (15.3) 100 (13.3) 0.89 12 (15.7) 37 (11.4) 0.67
All-cause death 1 (1.7) 19 (2.5) 0.33 1 (1.8) 6 (1.8) 0.54
Follow-up MI 3 (4.0) 12 (1.5) 0.4 3 (4.1) 5 (1.5) 0.59
TLR (per lesion) 11 (10.7) 98 (9.1) 0.98 11 (10.9) 31 (6.9) 0.24
TVR (per patient) 11 (13.7) 81 (11.0) 0.75 11 (14.1) 30 (9.4) 0.38
Values are n (%). P values of clinical outcomes were calculated with log-rank test (overall cohort)
or Klein–Moeschberger test (propensity-matched cohort).
MACE ¼ major adverse cardiac event; PMI ¼ periprocedural myocardial infarction; TLR ¼ target lesion
revascularization; TVR ¼ target vessel revascularization; other abbreviations as in Table 1.
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906which may explain the increase in PMI when manip-
ulating this vessel (stents, pre-, post-dilation, etc.). In
a pooled analysis of 11 PCI studies with bare-metal
stents and DES (including patients with acute coro-
nary syndromes), the occurrence of PMI, deﬁned as
CK-MB >3 the upper limit of normal within 48 h,
was about 7%, and more than one-half of cases were
attributed to side branch occlusion (29). Muramatsu
et al. (22) reported that BRS implantation is associated
with a higher incidence of post-procedural side
branch occlusions than everolimus-eluting stents are,
particularly in small side branches (6.0% in the
overall cohort and 10.5% in the group with side
branch reference vessel diameter &0.5 mm). In the
current study, the incidence of post-procedural side
branch occlusion in patients treated with SES was not
calculated due to the inability to review some
archived angiography ﬁlms.
Our deﬁnition of PMI used the one reported by
Vranckx et al. (23), which was also used in the
ABSORB trials. Although Abizaid et al. (30) did not
comment particularly on the rate of PMI, the inci-
dence of MI at 30 days in the ABSORB EXTEND study
was 2.1%, whereas in the more recent ABSORB II
(ABSORB II Randomized Controlled Trial: A Clinical
Evaluation to Compare the Safety, Efﬁcacy, and Per-
formance of Absorb Everolimus Eluting Bioresorbable
Vascular Scaffold System Against Xience Everolimus
Eluting Coronary Stent System in the Treatment of
Subjects With Ischemic Heart Disease Caused by DeNovo Native Coronary Artery Lesion), a 5% incidence
of PMI was reported (31). The higher incidence of PMI
in the current study is attributed to the severity of the
lesions treated and the more complex patient char-
acteristics. The missing values of cardiac enzymes
incorporated in clinical practice in recent years (CK-
MB, troponins) in the SES group (study period: be-
tween 2004 and 2009) did not allow for the use of a
more up-to-date deﬁnition of periprocedural MI that
would allow direct comparisons with the ABSORB II
trial. Of note, the introduction of troponins T or I was
ﬁrst introduced in the 2007 Academic Research Con-
sortium universal deﬁnition of MI (32). The ﬁgures of
PMI and their clinical relevance should be interpreted
with caution due to their arbitrary character, a limi-
tation highlighted also in the ABSORB II trial, which
demonstrated that PMI rates ranging from 1% to 30%
could be generated depending on the PMI deﬁnition
used.
In the current analysis, clinical outcomes at
30 days and 1 year were evaluated. No signiﬁcant
differences in MACE and their individual components
were observed between the 2 groups (BRS vs. SES: 0%
vs. 1.4% at 30 days and 15.7% vs. 11.4% at 1 year,
respectively). The increased MACE rate was attrib-
uted to an increased TVR (BRS vs. SES: 14.1% vs.
9.4%, p ¼ 0.36). In the ABSORB EXTEND study, Abi-
zaid et al. (30) reported ischemia-driven MACE rate
(cardiac death, MI, and ischemia-driven TLR) at 4.3%
at 1-year follow-up. The higher rate of MACE in our
study can be explained by the higher complexity of
the lesions treated and the broader deﬁnition of
MACE used. The BRS cohort in the current study re-
ﬂects real-world patients, true “all-comers” who un-
derwent implantation of BRS. Hence, 80% of the
lesions are classiﬁed as American College of Cardiol-
ogy/American Heart Association type B2/C, whereas
total scaffold length (mean length: 40.9  22.3 mm) is
longer than that reported in the ABSORB cohorts. The
deﬁnition of MACE in the current analysis did not
include TLR but did include TVR and also included
nonischemic driven TVR, which resulted in higher
MACE rates than were reported in previous studies.
Kimura et al. (4) reported the incidence of very late ST
and late TLR in the j-Cypher registry, which revealed
an ongoing risk of late ST of 0.26% per year and late
TLR of 2.2% per year without attenuation up to
5 years after SES implantation. On the other hand,
BRS struts are resorbed completely after 2 to 3 years
and may prevent late ST or target-lesion neo-
atherosclerosis. Even though there were no signiﬁ-
cant differences in clinical outcomes between groups
at 1 year, the BRS group may demonstrate better
long-term outcomes at 5 years after PCI than the SES
TABLE 4 Univariate and Multivariable Analyses for PMI
Univariable Multivariable
OR (95% CI) p Value OR (95% CI) p Value
Patient-related factors
Chronic kidney disease
(eGFR <60 ml/min/1.73 m2)
1.20 (0.61–2.35) 0.60
Previous MI 0.74 (0.37–1.47) 0.39
Previous CABG 0.96 (0.33–2.83) 0.95
Hypertension 1.14 (0.60–2.18) 0.69
Dyslipidemia 0.76 (0.41–1.40) 0.37
DM 0.89 (0.44–1.81) 0.75
Insulin-dependent DM 1.46 (0.49–4.36) 0.50
Lesion and procedure-related factors
Bioresorbable scaffold 1.86 (1.00–3.47) 0.05
LAD PCI 2.84 (1.24–6.50) 0.01 2.60 (1.16–5.81) 0.02
RCA PCI 0.46 (0.16–1.32) 0.15
In-stent restenosis 0.50 (0.12–2.14) 0.35
Chronic total occlusion 0.57 (0.17–1.89) 0.36
Type B2/C lesion (ACC/AHA) 1.64 (0.63–4.30) 0.31
Rotational atherectomy CS CS
Pre-dilation 4.37 (1.03–18.50) 0.05
Pre-balloon diameter, mm 1.55 (0.64–3.73) 0.33
Post-dilation 0.15 (0.02–0.93) 0.04
Post-dilation balloon/stent or
scaffold ratio per 0.1 increase
1.16 (0.83–1.62) 0.38
Mean pre-procedural RVD, mm 0.98 (0.56–1.73) 0.95
Mean pre-procedural DS, % 0.99 (0.97–1.00) 0.12
Acute gain 0.94 (0.58–1.53) 0.80
Post-dilation with larger balloon
than stent/scaffold diameter
1.61 (0.79–3.29) 0.19
Post-dilation with more than
rated pressure
1.55 (0.69–3.48) 0.29
Final MLD, mm 0.57 (0.64–2.24) 0.57
Total number of stents/scaffolds 1.33 (1.10–1.61) 0.003
Total stent/scaffold length,
10-mm increase/procedure
1.10 (1.03–1.18) 0.004
ASSA per 10-mm2 increase 1.07 (1.03–1.12) <0.001 1.07 (1.03–1.12) 0.001
CI ¼ conﬁdence interval; CS ¼ complete separation; DS ¼ diameter stenosis; OR ¼ odds ratio; other abbreviations
as in Tables 1 to 3.
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907group will. Studies with longer follow-up are eagerly
awaited to conﬁrm the long-term efﬁcacy of BRS
implantation.
Clinical predictors for PMI include multivessel
disease, stent length, lesion length, complex lesions,
presence of thrombus, treatment of saphenous vein
grafts, acute coronary syndromes, and use of glyco-
protein IIb/IIIa inhibitors (33–37). In the present
study, the rate of PMI was higher in the BRS group
than in the SES group (BRS: 13.1% vs. SES: 7.5%).
Univariate analysis revealed BRS, LAD PCI, pre-
dilation, post-dilation, total stent or scaffold num-
ber, total stent or scaffold length, and ASSA to be risk
factors for PMI. Multivariable analysis showed LAD
PCI and ASSA to be independent predictors of PMI.
Therefore, BRS with thinner struts with narrower
width may reduce the incidence of PMI and be more
suitable for the treatment of bifurcation lesions with
small side branches (e.g., in LAD). Of note, in the
current study we could not evaluate the impact of
strut thickness and total stent or scaffold “volume” as
we assessed 2 devices with similar strut thickness.
Furthermore, we were not able to analyze the impact
of stent/scaffold overlap on outcomes due to missing
archived angiographic ﬁlms in the SES group.
A larger strut volume could theoretically lead to more
frequent iatrogenic plaque ruptures and micro-
embolizations. To evaluate this possible mechanism
of PMI, plaque characteristics by intravascular ultra-
sound, ﬁnal TIMI (Thrombolysis In Myocardial
Infarction) ﬂow grade, myocardial blush grade, or
myocardial ﬁlling time should be simultaneously
evaluated in future studies. Higher rates and aggres-
sive pre- and post-dilation may cause iatrogenic pla-
que injury. Univariable analysis revealed both
pre- and post-dilation to be risk factors for PMI.
Oddly, in the current analysis, post-dilation had a
protective effect for PMI. However, the wide OR of
post-dilation (95% CI: 0.02 to 0.93) reﬂects the un-
balanced population after propensity matching (post-
dilations were performed in more than 98% in both
BRS and SES groups) and limits the interpretability of
the results. We also evaluated the effect of aggressive
post-dilation (balloon diameter larger than that of the
stent and use of higher than rated pressures) in this
study. Multivariate analysis revealed that none of
them is an independent predictor for PMI, despite
both exhibiting numerically increased OR for PMI
(post-dilation with larger balloon than stent/scaffold
[OR: 1.61, 95% CI: 0.79 to 3.29, p ¼ 0.19] and post-
dilation with more than rated pressure [OR: 1.55,
95% CI: 0.69 to 3.48, p ¼ 0.29]). To generalize the
impact of strut width and ASSA on PMI, larger studies
including different types of stents are required.STUDY LIMITATIONS. First, the main limitation in-
cludes the lack of randomization and angiographic
evaluation of side branch occlusion. Even though we
used propensity matching, it is still possible that
there are unadjusted confounders (particularly
related to lesion characteristics), which may have
inﬂuenced our results. Second, one should take into
account differences in PCI techniques (in particular
treatment of bifurcations) and in medical therapy
(e.g., administration of statin) due to the temporal
differences in BRS and SES implantation. Third, in the
current study we did not use the universal deﬁnition
of MI (32) due to the absence of data on troponin in
the SES group. Our deﬁnition of MI was the same as
that reported by Vranckx et al. (23), which was also
used in the ABSORB trials. Although it is possible to
PERSPECTIVES
WHAT IS KNOWN? Strut thickness is important for
stent deliverability, for endothelization, and to lower
intimal hyperplasia. Most of the current metal stents
have a strut thickness <100 mm. Strut width is a
parameter not frequently taken into account and
current metal stents have a strut width similar to their
thickness. The Absorb stent and most current BRS
have a strut width about 200 mm, higher than their
strut thickness. This manufacturing decision allows for
maintaining a good radial strength.
WHAT IS NEW? This study clearly demonstrates
that a wide strut can contribute to increased rates of
periprocedural myocardial infarction either by distal
embolisation or by completely covering a side branch
that does not become accessible any more with a wire.
WHAT IS NEXT? The next step would be to be able
to manufacture BRS with struts that are not so wide.
These new devices are expected to become available
in 2016. Presently, operators should be aware of this
limitation and they should be more liberal to protect a
side branch by placing a guidewire until the end of the
procedure. Placement of a guidewire may prevent the
occlusion of a side branch, although this can not be
fully guaranteed.
FIGURE 3 Rates of Outcomes Among Study Patients
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Kaplan-Meier curves are shown for major adverse cardiac events
(MACE) for both the bioresorbable scaffold (BRS) and sirolimus-
eluting stent (SES) groups. Event rates are Kaplan-Meier esti-
mates with log-rank p values.
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908compare our results with those of initial BRS trials,
the PMI criteria used may overestimate the true
incidence of PMI.
CONCLUSIONS
Despite their similar strut thicknesses, BRS implan-
tation was associated with a higher incidence of PMI
than SES implantation was. LAD PCI and ASSA were
independent predictors of PMI. Further larger,randomized controlled trials including different stent
types are required to evaluate the impact of strut
width or ASSA on PMI and long-term outcomes.
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